Literature DB >> 31203079

Risk Factors Predicting Recurrence of Bilateral Chronic Subdural Hematomas after Initial Bilateral Evacuation.

Jun Shen1, YaLong Gao2, Qifeng Li2, Ruixiang Ge1, Qifu Wang1, XiaoChun Jiang1, Xuefei Shao3.   

Abstract

BACKGROUND: Most patients with bilateral chronic subdural hematomas (bCSDH) undergo initial bilateral evacuation. Risk factors associated with the recurrence of bCSDH after initial bilateral evacuation have not been published to date. In this study, we aimed to identify risk factors related to recurrence of bCSDH after initial bilateral evacuation, and to develop a prognostic grading system for clinical reference.
METHODS: This study included 102 patients with bCSDH who underwent initial bilateral evacuation. Predictors of recurrence were identified via univariate analysis and multivariate logistic regression analysis. A prognostic grading system was created based on the independent predictors combined with a cutoff value. All cases were scored according to the prognostic grading system, and the recurrence rates of the different scores were reanalyzed.
RESULTS: Anticoagulant use (odds ratio [OR], 84.266; 95% confidence interval [CI], 13.113-541.522; P < 0.001), severe brain atrophy (OR, 11.551; 95% CI, 2.558-52.163; P = 0.001), and postoperative pneumocephalus volume (PostPV) (OR, 0.978; 95% CI, 0.957-1.000; P = 0.049) were independent risk factors for the recurrence of bCSDH after initial bilateral evacuation. The cutoff value of PostPV was >20.9484 cm3. A prognostic grading system was then developed, and the recurrence rates based on score were determined. Rates were 2.8% for a score of 0-1, 28.1% for a score of 2-3, and 100% for a score of 4-5, showing a significant increase in risk with increasing score (P < 0.001).
CONCLUSIONS: Anticoagulant use, severe brain atrophy, and PostPV were identified as independent risk factors for recurrence of bCSDH after initial bilateral evacuation. The prognostic grading system for recurrence of bCSDH after initial bilateral evacuation is reliable and applicable for clinical reference.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brain atrophy; Chronic subdural hematoma; Grading system; Recurrence rate

Year:  2019        PMID: 31203079     DOI: 10.1016/j.wneu.2019.06.016

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  5 in total

Review 1.  Middle Meningeal Artery Embolization: A Paradigm Shift in Approach of Chronic Subdural Hematoma.

Authors:  Hamza Hanif; Shanza Farook; Sajid S Suriya; Muhammad Umer Riaz Gondal; Muhammad Ibraiz Bilal; Abu Baker Sheikh
Journal:  J Community Hosp Intern Med Perspect       Date:  2022-09-09

2.  Risk factors for need of reoperation in bilateral chronic subdural haematomas.

Authors:  Shaian Zolfaghari; Jiri Bartek; Felix Djärf; San-San Wong; Isabelle Strom; Nils Ståhl; Asgeir S Jakola; Henrietta Nittby Redebrandt
Journal:  Acta Neurochir (Wien)       Date:  2021-04-02       Impact factor: 2.216

3.  The Efficacy of Adjuvant Corticosteroids in Surgical Management of Chronic Subdural Hematoma: A Systematic Review and Meta-Analysis.

Authors:  Guoqiang Tang; Jiabei Chen; Bin Li; Song Fang
Journal:  Front Neurol       Date:  2022-01-13       Impact factor: 4.003

4.  External validation of prognostic models predicting outcome after chronic subdural hematoma.

Authors:  Dana C Holl; Ana Mikolic; Jurre Blaauw; Roger Lodewijkx; Merijn Foppen; Korné Jellema; Niels A van der Gaag; Heleen M den Hertog; Bram Jacobs; Joukje van der Naalt; Dagmar Verbaan; K H Kho; C M F Dirven; Ruben Dammers; Hester F Lingsma; David van Klaveren
Journal:  Acta Neurochir (Wien)       Date:  2022-05-03       Impact factor: 2.816

5.  Predicting Chronic Subdural Hematoma Recurrence and Stroke Outcomes While Withholding Antiplatelet and Anticoagulant Agents.

Authors:  Mario Zanaty; Brian J Park; Scott C Seaman; William E Cliffton; Timothy Woodiwiss; Anthony Piscopo; Matthew A Howard; Kingsley Abode-Iyamah
Journal:  Front Neurol       Date:  2020-01-15       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.